Revive Therapeutics Ltd. · CSE:RVV
Revive Therapeutics — Investor Presentation (July 2021)
18 slides from Revive Therapeutics's investor presentation, July 2021
Slide 1: A Specialty Life Sciences Company – Corporate Presentation
A SPECIALTY LIFE SCIENCES COMPANY Corporate Presentation JULY 2021 US: FRANKFURT: RVVTF 31R Revive Therapeutics Ltd. | Office: 1-888-901-0036 | E-mail: [email protected]
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward- looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future f
Slide 3: Revive Therapeutics
REVIVE THERAPEUTICS Bucillamine Specialty life sciences company FDA approved Phase 3 clinical Developing novel Psilocybin focused on repurposing drugs trial for Bucillamine in the and Cannabidiol therapeutics Psilocybin for rare disorders and treatment of COVID-19 for various CNS and infectious dise
Slide 4: Pharmaceutical Strategy
PHARMACEUTICAL STRATEGY Clinical development of Targeting Rare Novel Uses, Targeting FDA Psilocybin, Cannabidiol Disorders and Formulations, and Designations: and Bucillamine Infectious Diseases, Delivery System Orphan, Fast track, Neurological Disorders, Breakthrough Mental Health and therapy Liver
Slide 5: Patent Portfolio
PATENT PORTFOLIO Title USPTO No. Status Use of Bucillamine in the Treatment of Infectious Diseases, including COVID-19 62/991,996 Provisional patent filed Use of Bucillamine in the Treatment of Gout US9662305 Issued on May 30, 2017 US 8642088 Issued on February 4, 2014 Drug Delivery System US 954542
Slide 6: Product Pipeline
PRODUCT PIPELINE Focus on Infectious Diseases, Psychedelics and Rare Disorders Stage of Product Indication Regulatory Status Development Infectious Diseases Phase 3 FDA approved Bucillamine COVID-19 (COVID-19) for Phase 3 Substance Use CTA with University of Psilocybin Disorder Phase 1 Wisconsin Met
Slide 7: Infectious Disease Opportunity
INFECTIOUS DISEASE OPPORTUNITY Received FDA approval for Focus on Bucillamine in Revive’s clinical history Bucillamine scientific rationale as FDA Phase 3 clinical trial the treatment of with Bucillamine an intervention for COVID-19 for COVID-19 infectious diseases (see Appendix) • Phase 3 study is
Slide 8: Psychedelics Opportunity
PSYCHEDELICS OPPORTUNITY Acquired Psilocin Pharma Corp. • Derrick Welch, Founder with 14 years of HC experience; 5 years in Cannabis • Worked with Xanthic Bio Pharma and Green Growth Brands • Developed water Soluble THC and CBD products (Beverages, effervescent tablets) Acquired Psilocybin Program f
Slide 9: Formulation & Delivery Technology
FORMULATION & DELIVERY TECHNOLOGY Delivering naturally extracted and synthetic psychedelics and cannabinoids DELIVERY SYSTEM Combines Tannin (antibacterial, antifungal, antioxidant, wound healing) and Chitosan (blood-clotting and antimicrobial) composites Releases (rapid, controlled, sustained), imp
Slide 10: Liver Disease Opportunity
LIVER DISEASE OPPORTUNITY Focus on Autoimmune Hepatitis (AIH) AIH - rare disease (~76k patients in US) Obtained FDA orphan drug status for CBD in the treatment of AIH causing liver inflammation Drawbacks of current therapies (steroids): Severe side effects in 13%, relapse after drug Seeking to file
Slide 11: Strategic Partners
STRATEGIC PARTNERS Psilocybin Oral Thin Film Delivery R&D partnership Infectious Diseases CRO Collaboration Psychedelic pharma License of cannabidiol for treatment Psilocybin Biosynthesis Psilocybin Collaboration of Autoimmune Hepatitis Collaboration © COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RI
Slide 12: Milestones
MILESTONES Q3 Q4 2021 2021 • FDA EUA Approval for Bucillamine in the treatment of COVID-19 • Complete Enrollment of Phase 3 study of Bucillamine in • FDA pre-IND meeting for Psilocybin oral thin film the treatment of COVID-19 • Initiate Phase 2 study for Psilocybin (TBI – Concussion) • Submit IND fo
Slide 13: Peer Comparison - COVID (Market Caps)
PEER COMPARISON - COVID (MARKET CAPS) $1.16B Market Caps $1.1B in $ CAD $750M $167M © COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. 13
Slide 14: Peer Comparison - Psychedelics (Market Caps)
PEER COMPARISON - PSYCHEDELICS (MARKET CAPS) $1.9B $1.9B Market Caps in $ CAD $500M $167M $55M © COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. 14
Slide 15: Team
TEAM Management Clinical & Regulatory Board of Directors • Michael Frank • Dr. Kelly McKee, Jr., MD, MPH • Michael Frank Chairman and CEO Chief Scientific Officer, Consultant Chairman and CEO • Carmelo Marrelli • Dr. Onesmo Mpanju, PhD • William Jackson Chief Financial Officer FDA Regulatory Affairs
Slide 16: Stock Information
STOCK INFORMATION Ticker 52-Week High/Low Market Cap RVV (CSE) | RVVTF (US) | 31R (Frankfurt) CAD $0.92 / $0.175 CAD ~ $167,000,000 Share Price Capital Structure CAD $0.53 (July 9, 2021) 315,634,551 common shares © COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. 16
Slide 17: Appendix – Bucillamine Scientific Rationale for COVID-19
APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19 Current antiviral interventions for influenza have exhibited modest efficacy, especially in improving mortality in at-risk populations, such as the elderly.1,2 Novel antivirals have been plagued by poor oral bioavailability and lack of efficac
Slide 18: Appendix – Bucillamine Scientific Rationale for COVID-19 References
APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19 References 1. Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
Revive Therapeutics — Investor Presentation (July 2021) on 6ix